Biogen and Vir Biotechnology have entered an antibody development and manufacturing agreement to develop Vir’s monoclonal antibodies against coronavirus.

Under the agreement, Biogen will provide cell line development, process development and clinical manufacturing for Vir’s monoclonal antibodies. Vir has discovered antibodies that bind to the novel coronavirus, and is testing whether they can treat or prevent the infection.

“Biogen is one of the global leaders in cell line and process development for advanced biologics; tapping into their capabilities will provide us with a U.S. base for supply and manufacture of antibody therapies,” said George Scangos, Vir’s CEO.